MicroRNA expression profiles in differentiated thyroid cancer, a review

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 1, 2013, Pages 74-80

  Li, Xinying ^a,b   Abdel Mageed, Asim B ^a   Mondal, Debasis ^a   Kandil, Emad ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Differentiated thyroid cancer; Fine needle aspiration biopsy; microRNA; Mutations

Indexed keywords

B RAF KINASE; MICRORNA; MICRORNA 1; MICRORNA 100; MICRORNA 125B; MICRORNA 130B; MICRORNA 138; MICRORNA 144; MICRORNA 146; MICRORNA 146B; MICRORNA 155; MICRORNA 181B; MICRORNA 187; MICRORNA 197; MICRORNA 199 5P; MICRORNA 221; MICRORNA 222; MICRORNA 30D; MICRORNA 346; MICRORNA 34B; MICRORNA 7; MICRORNA 768 3P; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; MICROARRAY ANALYSIS; MUTATION; NEEDLE BIOPSY; REVIEW; RNA GENE; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84870364751     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281
2. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
3. Busaidy NL and Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012; 2012: 618985.
4. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, Croce CM and Fusco A. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006; 13: 497-508.
5. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM and Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007; 14: 791-798.
6. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM and de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102: 19075-19080.
7. Kim HJ, Kim YH, Lee DS, Chung JK and Kim S. In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. J Nucl Med 2008; 49: 1686-1693.
8. Leone V, D'Angelo D, Rubio I, de Freitas PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco A. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab 2011; 96: E1388-1398.
9. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA and Baloch ZW. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007; 18: 163-173.
10. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ 3rd and Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008; 21: 1139-1146.
11. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC and Liu RT. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010; 20: 489-494.
12. Nikiforova MN, Tseng GC, Steward D, Diorio D and Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008; 93: 1600-1608.
13. Weber F, Teresi RE, Broelsch CE, Frilling A and Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 3584-3591.
14. Rossing M, Borup R, Henao R, Winther O, Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sorensen C, Kiss K, Bennedbaek FN and Nielsen FC. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. J Mol Endocrinol 2012; 48: 11-23.
15. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, Kroll TG and Nikiforov YE. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-2326.
16. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C and Zedenius J. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 4440-4445.
17. Kroll TG. Molecular events in follicular thyroid tumors. Cancer Treat Res 2004; 122: 85-105.
18. Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M and Bidart JM. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol 2004; 151: 367-374.
19. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M and Bidart JM. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 2005; 167: 223-231.
20. Nikiforov YE and Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-580.
21. Koenig RJ. Detection of the PAX8-PPARgamma fusion protein in thyroid tumors. Clin Chem 2010; 56: 331-333.
22. Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, Guenther SM, O'Leary JJ and Sheils OM. Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Mol Cancer 2008; 7: 89.
23. Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ and Sheils O. Effect of ret/PTC 1 rearrangement on transcription and posttranscriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 2006; 5: 70.
24. Cahill S, Smyth P, Denning K, Flavin R, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ and Sheils O. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 2007; 6: 21.
25. Sheu SY, Grabellus F, Schwertheim S, Handke S, Worm K and Schmid KW. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Horm Metab Res 2009; 41: 482-487.
26. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL and Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
27. Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2012; 118: 3426-3432.
28. Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR and Nissan A. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 2011; 21: 111-118.
29. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA and Kebebew E. Evaluation of candidate diagnostic micrornas in thyroid fine-needle aspiration biopsy samples. Thyroid 2012; 22: 285-291.
30. Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA and Kebebew E. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol 2011; 18: 3443-3452.
31. Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, Nagy R, Farrell T, Ringel MD, de la Chapelle A, Kloos RT and He H. MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. Thyroid 2012; 22: 9-16.
32. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE and Nikiforova MN. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011; 18: 2035-2041.
33. Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH and Kebebew E. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2012; 118: 3426-3432.
34. Schwertheim S, Sheu SY, Worm K, Grabellus F and Schmid KW. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 2009; 41: 475-481.
35. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ and Lowe SW. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289-1295.
36. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M and Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.